Gentaur Pub

#22237896   // Save this To Up

Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus.

Enzyme-linked immunosorbent assay (ELISA) is normally used to quantify the amount of serum IgG antibodies against measles, mumps, rubella, and varicella-zoster virus (MMRV). However, this method is time- and material-consuming. Therefore, a multiplex immunoassay for the simultaneous quantitative detection of antibodies against MMRV was developed. In-house as well as commercially available antigens can be used, making the assay available for all laboratories. The multiplex assay is much more sensitive than the separate ELISAs and has a high specificity, and only 5 μl of serum is needed. Heterologous inhibition did not exceed 11.5%, while homologous inhibition varied between 91.3 and 97.9%. Good correlations with the in-house ELISAs for measles (R(2) = 0.98), mumps (R(2) = 0.97), and rubella (R(2) = 0.97) virus as well as with the ELISA kit for varicella-zoster virus (R(2) = 0.95) were obtained. In conclusion, the MMRV multiplex assay is a good alternative to the conventional ELISAs and suitable for use in serosurveillance and vaccine studies.

2665 related Products with: Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus.

Measles Virus Nucleoprote Viral antibodies, anti-R Measles Virus nucleoprote Hepatitis C Virus antibod Human Serum Albumin antib Human Serum Albumin antib Feline Leukemia Virus gp7 Feline Leukemia Virus gp7 Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod

Related Pathways

#17368781   // Save this To Up

Analysis of factors associated with varicella-zoster virus susceptibility among children 0-12 years old in Taiwan.

Varicella is a highly infectious disease caused by varicella-zoster virus (VZV). The aim of this study was to explore the geographical difference of VZV antibody seroprevalence among children in private vaccination areas in Taiwan, controlling for potential factors relating to varicella susceptibility.

1796 related Products with: Analysis of factors associated with varicella-zoster virus susceptibility among children 0-12 years old in Taiwan.

Varicella Zoster Virus (V Varicella Zoster Virus (V Human Varicella zoster vi Varicella Zoster Virus (V Biotin Blocking Kit for Rubella virus capsid (C) Human Epstein-Barr Virus Caspase-12 Inhibitor Z-AT Caspase-12 Inhibitor Z-AT Caspase 12 Inhibitor 100 Caspase 12 Inhibitor Z AT Caspase-12 Inhibitor Z-AT

Related Pathways

#17290724   // Save this To Up

Seroprevalence of antibody to varicella among Somali refugees.

To determine the seroprevalence of varicella antibody among recent Somali refugees living in Olmsted County, Minnesota, and to estimate the risk of varicella-zoster virus (VZV) infection in this group.

2872 related Products with: Seroprevalence of antibody to varicella among Somali refugees.

Shiga Toxin 1 antibody, M Shiga Toxin 2 antibody, M Cholera toxin antibody, M Clostridium botulinum D T Clostridum difficile toxi Clostridum difficile toxi Clostridum difficile toxi Clostridum difficile toxi Clostridum difficile toxi Clostridum difficile toxi Clostridum difficile toxi Diphtheria toxin antibody

Related Pathways

#16459000   // Save this To Up

Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age.

To investigate the persistence of maternal IgG antibodies against Varicella-Zoster virus (VZV) in infants and young children.

1452 related Products with: Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age.

Varicella Zoster Virus (V Human Varicella zoster vi Viral antibodies, anti-R HIV1 integrase antibody, Measles Virus Nucleoprote Hepatitis C Virus antibod Feline Leukemia Virus gp7 Feline Leukemia Virus gp7 Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod

Related Pathways

#15286822   // Save this To Up

A simple and cheaper in house varicella zoster virus antibody indirect ELISA.

We have developed a cheaper an simple in house indirect ELISA that uses the live attenuated VZV vaccine as a coating antigen. The alternative ELISA had an agreement of 94% when compared with a commercial VZV ELISA kit. Moreover, our ELISA proved to be more reliable than the kit when assessing true negative samples. By adding a standard serum, we were able to produce results in international units per millilitre. Also, the addition of an extra step with 8M urea allowed the assessment of VZV IgG avidity without excessive costs. The cost per sample to test VZV IgG was 2.7 times cheaper with our ELISA, allowing the testing of many samples without the burden of production of VZV antigen in the laboratory.

1880 related Products with: A simple and cheaper in house varicella zoster virus antibody indirect ELISA.

HA (Influenza A Virus Hem Rabbit Anti-Polyprotein(H Rabbit Anti-IAA (Indole-3 Rabbit Anti-Integrin alph Rabbit Anti-TNIP2 ABIN2 T Human Varicella zoster vi Human anti-parainfluenza Human anti hepatitis A vi Porcine Transmissible Gas Human interleukin 2(IL-2) Human Anti-E Antigen of H Human Anti-Core Antigen o

Related Pathways

#10774265   // Save this To Up

Immunity to varicella zoster virus in young Israeli adults.

Chickenpox is a highly contagious childhood infection caused by varicella zoster virus, a virus of the herpes family. Although a mild and self-limiting disease in otherwise healthy children, chickenpox can be a complicated and even life-threatening disease in adults, pregnant women and immunosuppressed individuals. Among infants whose mothers had varicella during the first trimester of pregnancy, 2-3% will develop a congenital VZV syndrome that includes a combination of scarring, limb deformation, central nervous system impairment and ocular injury. In 1974, a live attenuated virus vaccine against VZV was developed in Japan and has been thoroughly tested for safety, efficacy and long-term effects. In March 1995 the vaccine was licensed in the U.S. for use in healthy children only.

2844 related Products with: Immunity to varicella zoster virus in young Israeli adults.

Varicella Zoster Virus (V Varicella Zoster Virus (V Human Varicella zoster vi Varicella Zoster Virus (V FIV Core Ag, recombinant Human Epstein-Barr Virus Mouse Epstein-Barr Virus Recombinant Human Interfe Recombinant Influenza B V Recombinant Influenza B V Recombinant Influenza B V Native Influenza A Virus

Related Pathways